Akeso Announces NMPA Acceptance of sNDA for Ivonescimab in Combination with Chemotherapy for First-Line Biliary Tract Cancer

Résumé détaillé
HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted…
The sNDA is supported by results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-GI1 study (AK112-309). The study evaluated ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy, a current global standard of care for first-line BTC. At a pre-specified interim analysis, the study met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement. All key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR), were also met.
HARMONi-GI1 is the first Phase III study in biliary tract cancer to demonstrate a statistically significant overall survival benefit versus a PD-L1 inhibitor plus chemotherapy regimen. The results were presented as a Late-Breaking Abstract in an oral presentation at the ESMO Presidential Symposium in October 2026.
The global registrational development of ivonescimab in biliary tract cancer is progressing. The Phase II/III study EA2251, conducted in collaboration with Summit Therapeutics, and the ECOG-ACRIN Cancer Research Group, has been initiated. This study will evaluate ivonescimab plus chemotherapy versus pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of advanced BTC. EA2251 represents the seventh international registrational clinical trial of ivonescimab.
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly…
Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)
